Drug Trial Radar · NCT06757634
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,180
Planned (sponsor's estimate)
Start
Jul 24, 2025
Primary completion
Mar 31, 2029
Study completion Jul 30, 2033
Sponsor
- Lead sponsor
- Celcuity IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Conditions
- Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + FulvestrantDrug
Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off Other Names: • PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle. Other Names: • IBRANCE Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks Other Names: • Faslodex
Arm B: Ribociclib + FulvestrantDrug
Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle Other Names: • KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4 weeks Other Names: • Faslodex
Arm C: Gedatolisib + Palbociclib + LetrozoleDrug
Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle. Drug: Letrozole Participants will receive oral letrozole daily.
Arm D: Ribociclib + LetrozoleDrug
Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle Drug: Letrozole Participants will receive oral letrozole daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From date of randomization to the date of death due to any cause, up to approximately 48 months
Locations
239 sites in 25 countries. Site status is shown where the registry gives one.
St Bernards Medical Center
Jonesboro, Arkansas · Not yet recruiting
CARTI Cancer Center
Little Rock, Arkansas · Not yet recruiting
City of Hope Medical Center
Duarte, California · Not yet recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
UCLA Hematology Oncology Santa Monica
Los Angeles, California · Recruiting
Cancer Care Associates
Redondo Beach, California · Not yet recruiting
UC San Diego Moores Cancer Center
San Diego, California · Not yet recruiting
University of Colorado Hospital - Cancer Center
Aurora, Colorado · Not yet recruiting
BRCR Medical Center, Inc- Internal Medicine
Plantation, Florida · Recruiting
BRCR Medical Center, INC
Tamarac, Florida · Recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Mercy Health-Paducah Cancer Center
Paducah, Kentucky · Recruiting
American Oncology Partners, P.A.
Bethesda, Maryland · Withdrawn
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Not yet recruiting
Henry Ford Health System
Detroit, Michigan · Recruiting
Saint Luke's Cancer Institute
Kansas City, Missouri · Recruiting
Washington University School of Medicine in Saint Louis
St Louis, Missouri · Recruiting
SCL Health - Cancer Centers of Montana
Billings, Montana · Recruiting
Christus Saint Vincent Regional Cancer Center
Santa Fe, New Mexico · Not yet recruiting
Weill Cornell Medical College - NewYork-Presbyterian Hospital
New York, New York · Recruiting
Clinical Research Alliance, Inc.
Westbury, New York · Recruiting
Stefanie Spielman Comprehensive Breast Center at Olentangy River Road
Columbus, Ohio · Recruiting
OHSU Research Integrity
Portland, Oregon · Not yet recruiting
Rittenhouse Hematology/Oncology
Philadelphia, Pennsylvania · Withdrawn
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Not yet recruiting
The Center for Cancer and Blood Disorders - Breast Center
Fort Worth, Texas · Not yet recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Mays Cancer Center
San Antonio, Texas · Recruiting
Bon Secours St. Francis Medical Oncology Center
Midlothian, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Centro de Oncologia e Investigacion Buenos Aires COIBA
Buenos Aires, Argentina · Not yet recruiting
Pergamino Clinic
Buenos Aires, Argentina · Not yet recruiting
Centro de Investigaciones Médicas y Desarrollo LC
Buenos Aires, Argentina · Not yet recruiting
Fleischer Medical Center (Centro Medico Fleischer)
Buenos Aires, Argentina · Not yet recruiting
Fundacion Respirar
Buenos Aires, Argentina · Not yet recruiting
Centro Oncológico Korben
Buenos Aires, Argentina · Not yet recruiting
Alexander Fleming Institute
Buenos Aires, Argentina · Not yet recruiting
Center for Medical Education and Clinical Research (CEMIC)
Buenos Aires, Argentina · Not yet recruiting
Cordoba Oncology Institute (IONC)
Córdoba, Argentina · Not yet recruiting
Fundación CORI
La Rioja, Argentina · Not yet recruiting
Showing 40 of 239 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.